We report here that amyotrophic lateral sclerosis-linked superoxide dismutase 1 (SOD1) mutants with different biochemical characteristics disrupted the blood-spinal cord barrier in mice by reducing the levels of the tight junction proteins ZO-1, occludin and claudin-5 between endothelial cells. This resulted in microhemorrhages with release of neurotoxic hemoglobin-derived products, reductions in microcirculation and hypoperfusion. SOD1 mutant-mediated endothelial damage accumulated before motor neuron degeneration and the neurovascular inflammatory response occurred, indicating that it was a central contributor to disease initiation.
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SOD1 mutations that are linked to amyotrophic lateral sclerosis (ALS) are thought to cause disease by toxicity that is derived from nonneuronal neighboring cells, particularly microglia and astrocytes, contributing to motor neuron degeneration and disease progression 1, 2 . The role of blood vessels in the pathogenesis of ALS, however, is poorly understood. Recent reports have documented ultrastructural changes at the blood-spinal cord barrier (BSCB) 3 and BSCB leakage to Evans blue 4 midway through disease progression using transgenic overexpression of a dismutase-active, ALS-linked SOD1 human mutant (SOD1 G93A ) as a model for the disease. It is unknown whether damage to the vasculature is a common feature of dismutase-active and dismutase-inactive SOD1 mutants that are causative of ALS, and whether these mutations affect microcirculation in the spinal cord. Here, we used mouse models that expressed SOD1 mutants with different biochemical characteristics to address these questions. (Experimental methods are described in the Supplementary Methods online.)
The BSCB to serum proteins appeared to be nearly intact in the lumbar cord of control mice, as indicated by negligible IgG staining in parenchyma (Fig. 1a,b) . In contrast, substantial focal IgG deposits from blood vessels were seen in the lumbar cords of dismutase-active SOD1 G37R and dismutase-inactive SOD1 G85R mutant mice at 3.5 and 6.5 months of age, respectively. The intensity of IgG leakage in SOD1 G37R , SOD1 G85R and SOD1 G93A mutants indicated that there was a substantial breakdown of the BSCB to serum proteins that, in each mouse line, occurred either before or contemporaneous with the initial axonal withdrawal from neuromuscular junctions 5, 6 , and occurred before motor neuron loss (Fig. 1c) . In each line, we observed a further increase in IgG leakage during disease progression. Notably, mice overexpressing human wild-type SOD1 (SOD1 WT ) 7 (levels at or well above the levels of mutant SOD1 in each of the ALS lines) did not develop changes in BSCB permeability to IgG (assayed at 4 and 7 months of age) compared with wild-type littermate controls.
Prussian blue staining from presymptomatic SOD1 G93A , SOD1 G37R and SOD1 G85R mice identified deposits of hemosiderin, a hemoglobin derivative, in and outside of motor neurons (Fig. 1d) , suggesting that microhemorrhages were occurring. All of the studied SOD1 mutants showed significant hemosiderin accumulations presymptomatically (P o 0.05; Fig. 1e ) and well before motor neuron loss. Hemosiderin deposition worsened with disease progression but was absent in agematched C57BL/6 and B6SJL littermate controls and mice expressing SOD1 WT (Fig. 1d,e ). Deposits were found mainly in the anterior horn ( Supplementary Fig. 1 online) .
To determine whether inflammatory vascular changes take place before BSCB disruption, we studied the accumulation of monocyte chemoattractant protein-1 (MCP-1, also known as CCL2) and cyclooxygenase 2 (Cox2, also known as Ptgs2), two inflammatory markers mediating blood-brain barrier opening 8 , and intercellular adhesion molecule-1 (Icam-1), a marker of activated endothelium 9 , in SOD1 G93A mutants. At 2 months of age, when the BSCB was already disrupted in SOD1 G93A mice (Fig. 1a,b,d,e) , there was no increase in Ccl2 (Fig. 1f) , Ptgs2 or Icam1 mRNA levels (Fig. 1g,h ) and/or immunostaining ( Supplementary Figs. 2 and 3 online) . In contrast, the expression of these markers was elevated at 3.5 months of age. Our findings are consistent with prior observations in human SOD1 G93A mutants that showed no microglia activation at 2 months of age 10 (confirmed in our study; data not shown), an increased MCP-1 expression at the symptomatic and end stages, but not at an early stage 9, 10 , and increased mRNA levels for numerous potential mediators involved in microglia propagation at symptomatic and end stages, but not at an early presymptomatic stage 1, 9 . Thus, the BSCB breakdown observed at an early presymptomatic stage in SOD1 G93A mutants precedes the neurovascular inflammatory response. At later stages, however, activation of different inflammatory markers probably contributes to the observed progressive BSCB breakdown (Fig. 1b,e) .
The early breakdown of the BSCB that occurs before inflammatory changes could be a consequence of direct toxicity of SOD1 to the endothelium and disruption of tight-junction integrity. To test this, we used immunoblotting of extracts of isolated spinal cord capillaries, a site of the BSCB in vivo, to measure the levels of proteins that are essential for the formation of the barrier in comparison with proteins that do not participate in the barrier formation. As expected, human SOD1 mutant protein was expressed in the endothelium of SOD1 G93A mice (Fig. 2a) . The endogenous expression of mouse Sod1 was not altered by the human SOD1 G93A gene. In contrast, the levels of ZO-1, occludin and claudin-5 ( Fig. 2a) , the tight junction proteins that mediate low paracellular permeability between adjacent endothelial cells 8 , were reduced by 40-60% in 2-month-old SOD1 G93A mice. Accumulation of other endothelial antigens that are not involved in the formation of the barrier (for example, the glucose transporter Glut1 and von Willebrand factor; data not shown) 8 was not affected by the SOD1 mutation (Fig. 2a) . Immunoblot analysis of spinal cord capillaries derived from mice expressing ALS-linked SOD1 mutants that retained full (SOD1 G37R ) or no (SOD1 G85R ) dismutase activity, but not SOD1 WT , revealed that there was a similar downregulation of the tight junction proteins in the endothelium (Fig. 2b) at ages before the initiation of motor neuron degeneration (3.5 and 6.5 months, respectively 6 ). Immunostaining for ZO-1 in the vasculature corroborated that its expression was reduced by 40-50% in SOD1 G37R and SOD1 G85R mice ( Supplementary Fig. 4 online) . These data suggest that SOD1 mutant toxicity specifically disrupts the BSCB by reducing the accumulation of critical tight junction proteins in the endothelium.
We found significant (P o 0.01) 10-15% reductions in the total length of capillaries in the lumbar cord of SOD1 G93A , SOD1 G37R and SOD1 G85R mice compared with wild-type littermate controls or SOD1 WT mice (Fig. 2c) at stages before motor neuron loss (Fig. 1c) 5, 6 and before inflammatory changes (Fig. 1f-g ). Electron microscopy of SOD1 G37R , SOD1 G85R or SOD1 G93A mutant mice at ages before denervation (3.5, 6 and 2 months, respectively) revealed focal accumulations of extracellular fluid (edema) between the capillary vessel wall and motor neurons, and/or collapsed capillary lumens in all three models (Fig. 2d) . In contrast, littermate controls showed a normal vascular-neuronal relationship (Fig. 2e) .
We next tested whether the BSCB breakdown, the reductions in total capillary length and the microhemorrhages affected blood flow. Direct measurement (with 14 C-iodoantpyrine) revealed that there were 30-45% reductions in blood flow through the cervical and lumbar cord, respectively, by 2 months of age in SOD1 G93A mice (Fig. 2f) . Early reductions in the blood flow were most prominent in the anterior horn in the lumbar cord, the region most affected in each of the mouse models ( Supplementary Fig. 5 online) . Reductions in flow would be expected to create chronic hypoperfusion, which could aggravate motor neuron injury and functional outcome, as shown in mice with a mutation that eliminates hypoxia-responsive induction of the vascular endothelial growth factor A gene (Vegfa d/d ) and that develop late-onset motor neuron degeneration 11 . Ischemia worsened motor neuron degeneration and functional outcome in Vegfa d/d mice, whereas the absence of hypoxic induction of Vegfa in mice that develop motor neuron disease from the expression of SOD1 G93A yields substantially reduced survival 12 .
Free hemoglobin released from extravasated red blood cells is toxic to neurons 13 by releasing neurotoxic products (for example, free iron) associated with the generation of reactive oxygen species, lipid peroxidation and neuronal cell death. Consistent with the hemoglobinmediated damage that has been reported in other contexts 13 , in SOD1 G37R and SOD1 G85R mice, but not in SOD1 WT , we observed a significant increase (P o 0.05) in the susceptibility of N2a neuronal cells 14 to hemoglobin-mediated cell death (Fig. 2g) .
More recent studies reported an increase in the cerebrospinal fluid/ serum albumin ratio in a subset (o30%) of sporadic ALS patients 15 , but spinal cord tissue and BSCB have not yet been analyzed directly. Our study demonstrates that changes to the vasculature probably make an important contribution to the degeneration of large motor neurons in familial models of ALS. Moreover, we have shown that damage to the vasculature is one of the earliest pathologic events in the toxic cascade initiated by both dismutase-active and dismutase-inactive SOD1 mutants, which includes a disruption of the BSCB mediated by reduced levels in the endothelium of the essential tight junction proteins ZO-1, occludin and claudin-5, and resulting in both microhemorrhages that release neurotoxic products and reductions in microcirculation and hypoperfusion ( Supplementary Fig. 6 online) . All of this evidence supports the idea that mutant-mediated damage to the vasculature contributes to initiating non-cell autonomous killing of motor neurons in inherited ALS. Genetic or pharmacologic interventions targeted specifically to the endothelium will help to determine both the causality between BSCB leakage and motor neuron degeneration and how such damage may delay disease onset and/or its progression.
Note: Supplementary information is available on the Nature Neuroscience website. 
